IMARC Group, a leading market research company, has recently released a report titled "Cell and Gene Therapy Market by Therapy Type (Cell Therapy, Gene Therapy), Indication (Cardiovascular Disease, Oncology Disorder, Genetic Disorder, Infectious Disease, Neurological Disorder, and Others), Delivery Mode (In-Vivo, Ex-Vivo), End User (Hospitals, Cancer Care Centers, Pharmaceutical & Biotechnology Companies, and Others), and Region 2025-2033." The study provides a detailed analysis of the industry, including the global cell and gene therapy market size, share, Growth, trends, and forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

MARKET OVERVIEW

The global Cell and Gene Therapy Market is expected to grow at a CAGR of 14.88% during the forecast period 2025-2033. The market size was USD 575 million in the base year 2024. This growth is driven by rapid biotechnology advancements, increased prevalence of chronic diseases, supportive regulatory frameworks, and expanding manufacturing investments. These therapies offer personalized and potentially curative treatments, especially targeting oncology and genetic disorders.

STUDY ASSUMPTION YEARS

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

CELL AND GENE THERAPY MARKET KEY TAKEAWAYS

• Current Market Size: USD 575 million (2024)
• CAGR: 14.88%
• Forecast Period: 2025-2033
• Advances in biotechnology and genetic research, such as CRISPR-Cas9 and viral vector technologies, are key growth drivers.
• Oncology disorders dominate the market due to rising cancer prevalence and research investments.
• North America holds the largest market share, benefiting from robust R&D and supportive regulatory environments.
• Hospitals represent the largest end-user segment, driven by adoption and strategic collaborations.
• Increasing public and private investments facilitate innovation and commercialization of novel therapies.

Claim Your Free “Cell and Gene Therapy Market” Insights Sample PDF: https://www.imarcgroup.com/cell-gene-therapy-market/requestsample

MARKET GROWTH FACTORS

Cell and gene therapies are an extension of improvements in biotechnology and research into gene sequencing, and use of technology such as CRISPR-Cas9 gene editing and viral vectors. They are able to modify or replace genes within cells, for previously incurable or hard-to-treat diseases. As techniques have continuously developed, both public and private investment has resulted in the development of new therapies that are more targeted and result in better outcomes.

Chronic diseases prevail and the population ages so those factors drive the cell and gene therapy market to grow worldwide. Because of an increasing number of neurodegenerative disorders, cancers, and cardiovascular diseases, cell and gene therapy has progressed toward treating the unmet needs of medicine by placing modified cells or genetic material in the cells for the development of new functional tissues. In addition, several of these therapies can be tailored to personal genetics, making them attractive to both healthcare providers and patients alike.

Regulatory help and fast tracks in the form of U.S. FDA breakthrough therapy designation and the accelerated approval pathway by the European Medicines Agency have led to more investment and faster market acceptance. This support increases the number of approved therapies available and increases partnerships between pharmaceutical companies and research institutions.

MARKET SEGMENTATION

Therapy Type:

• Cell Therapy
• Stem Cell
• Pluripotent Stem Cell
• Cancer Stem Cell
• Adult Stem Cell
• Non-Stem Cell
• T Cells
• Natural Killer
• Others
• Gene Therapy

Cell therapy involves transplanting or manipulating living cells to repair tissues. Stem cells (pluripotent, cancer, adult) offer regenerative potential. Non-stem cells include immune cells like T cells and natural killer cells used for targeted therapies. Gene therapy focuses on altering genetic material to correct faulty genes.

Indication:

• Cardiovascular Disease
• Oncology Disorder
• Genetic Disorder
• Infectious Disease
• Neurological Disorder
• Others

These indications represent the diseases treated by cell and gene therapies. Oncology disorder holds the largest market share due to high cancer prevalence and ongoing research investments.

Delivery Mode:

• In-Vivo
• Ex-Vivo

In-vivo therapies deliver genes or cells directly into the patient’s body using targeted technologies, such as viral vectors. Ex-vivo therapies modify cells outside the body before reinfusion, benefiting from improved genetic engineering and bioprocessing techniques.

End User:

• Hospitals
• Cancer Care Centers
• Pharmaceutical & Biotechnology Companies
• Others

Hospitals dominate as the primary end users, driven by increased awareness, acceptance, strategic collaborations, and favorable regulations supporting therapy adoption.

Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America holds the largest share of the cell and gene therapy market. This dominance is attributed to robust research and development investments, supportive regulatory policies such as expedited FDA pathways, and a well-established healthcare infrastructure. The region benefits from a high prevalence of chronic diseases and strong collaborations between academia and industry, fostering innovation and market expansion.

RECENT DEVELOPMENTS & NEWS

• In March 2023, Spark Therapeutics announced work on a USD 575 million gene therapy innovation center in Philadelphia.
• In August 2023, Kolon TissueGene raised USD 29.6 million aiming to develop cell and gene therapies targeting osteoarthritis of the knee.
• In June 2023, Amgen received U.S. FDA approval for the supplemental Biologics License Application for BLINCYTO® (blinatumomab) to treat CD19-positive B-cell precursor acute lymphoblastic leukemia in adults and pediatric patients.

KEY PLAYERS

• Amgen Inc.
• Biogen
• Bluebird bio, Inc.
• Bristol-Myers Squibb
• Gilead Science
• Kolon TissueGene Inc.
• Orchard Therapeutics plc.
• Pfizer Inc
• Renova Therapeutics
• Spark Therapeutics, Inc.

Ask Analyst For Request Customization: https://www.imarcgroup.com/request?type=report&id=6964&flag=E

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

ABOUT US

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

CONTACT US

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: [email protected],

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302